{
  "id": 3831345,
  "title": "First Oral Option for Dermatomyositis Gets FDA Green Light",
  "url": "https://urgent.news/2026/08/27/first-oral-option-for-dermatomyositis-gets-fda-green-light",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-27T21:40:11.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/dermatology/generaldermatology/122799"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- The FDA approved the first oral treatment option for the autoimmune disorder dermatomyositis. Brepocitinib (Lisraya) is indicated for adults with the rare condition, which causes chronic inflammation, progressive muscle weakness...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}